- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
- Interventions
- IPI-549 (eganelisib), Nivolumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 11
- States / cities
- San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 6,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Aging
- Interventions
- Dance Group, Strength, Stretching, Stability, Walking, Walking + Nutrition
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 60 Years to 79 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Esophageal Cancer, Appendiceal Cancer
- Interventions
- CYTALUX™ (pafolacianine)
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sarcoma, Bone Sarcoma, Soft Tissue Sarcoma (STS)
- Interventions
- Exercise Triage and Personalized Exercise Program
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 15 Years to 39 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer
- Interventions
- ABT-869, paclitaxel, Placebo for ABT-869
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- San Francisco, California • Harvey, Illinois
- Conditions
- Bladder Cancer
- Interventions
- Baseline Strength Test, Exercise
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cancer
- Interventions
- ARRY-380, HER2 inhibitor; oral
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Atezolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- COVID-19
- Interventions
- Remdesivir, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 106
- States / cities
- Anaheim, California • Berkeley, California • Burlingame, California + 76 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SAR402663, Diluent
- Biological · Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 19 more
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Arsenic trioxide
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pharmacogenetics
- Interventions
- Medication Therapy Management, Pharmacogenetic testing
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Interventions
- Sym021, Sym022, Sym023
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab IV, No Intervention
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Dietary Intervention, Dietary Proteins, Dietary Assessment, Cognitive Ability, General
- Interventions
- Ready-to-eat beef in frozen, 5-oz packages, Ready-to-eat beef in frozen, 1-oz packages
- Dietary Supplement
- Lead sponsor
- University of Nebraska Lincoln
- Other
- Eligibility
- 19 Years to 24 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV, Cervical Cancer Stage IIIB, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB, Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Vulvar Cancer, Stage III, Vulvar Cancer, Stage IV, Vaginal Cancer Stage III, Vaginal Cancer Stage IVA, Vaginal Cancer Stage IVB
- Interventions
- Strong Together serious game
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Kidney Disease
- Interventions
- KBP-5074
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Diabetes Mellitus, Hemodialysis Complication, Cardiovascular Complication, Quality of Life
- Interventions
- Tennant Biomodulator ®
- Device
- Lead sponsor
- Hamad Medical Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- Tovecimig, Irinotecan, Leucovorin, 5-Fluorouracil (5-FU)
- Biological · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Voice Disorders
- Interventions
- Microlaryngoscopy, Voice Evaluation, Airway Reconstruction
- Procedure
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Locally Advanced or Metastatic NRAS Mutant Melanoma
- Interventions
- LEE011, MEK162
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- San Francisco, California • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Sarcopenia, Aging
- Interventions
- Exercise training
- Other
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 60 Years to 80 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Opioid Use Disorder
- Interventions
- Medication for opioid use disorder, psychotherapy
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2030
- U.S. locations
- 1
- States / cities
- Irvine, California